Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

Figure 3 Representation of cumulative survival in patients treated with primary tumor surgery and metastases with peptide receptor radionuclide therapy (green) and patients treated only with peptide receptor radionuclide therapy (blue). A: For patients treated with primary tumor surgery, the probability of long-term survival is higher when treated with peptide receptor radionuclide therapy, showing the existence of a directly proportional relationship between survival and surgical treatment; B: The patients treated with metastases.